Acute toxicity and outcomes of radiotherapy plus cetuximab in locally advanced head and neck cancer
-
- Yamauchi Moriyasu
- Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine, Saga University
-
- Kawasaki Kanako
- Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine, Saga University
-
- Shimazaki Eriko
- Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine, Saga University
-
- Minesaki Akimichi
- Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine, Saga University
-
- Monji Mikio
- Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine, Saga University
-
- Suzuki Kumiko
- Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine, Saga University
-
- Shimazu Rintaro
- Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine, Saga University
-
- Kuratomi Yuichiro
- Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine, Saga University
Bibliographic Information
- Other Title
-
- 当科における局所進行頭頸部癌に対するセツキシマブ併用放射線療法の早期有効性と有害事象の検討
Search this article
Description
We retrospectively reviewed the acute toxicity and efficacy of locally advanced head and neck cancer patients treated with radiotherapy plus cetuximab. Forty patients with head and neck cancer comprising 3 nasopharynx, 13 oropharynx, 21 hypopharynx and 3 larynx were analyzed. Clinical stages at diagnosis were Ⅲ in 8, ⅣA in 30 and ⅣB in 2 cases. The treatment completion rate was 92.5%. Grade 1 or 2 infusion reactions were observed in 2 patients. Three patients developed grade 2 interstitial lung disease. Grade 3 or higher adverse events were as follows: radiation dermatitis in 15, oral/pharyngeal mucositis in 14, aspiration pneumonia in 2, and laryngeal edema in 1 case. Response rates were 100% in nasopharynx, 92.3% in oropharynx, 83.3% in hypopharynx, 100% in larynx, and 89.2% in total. These findings of toxicity and efficacy are similar to those of recent publications.
Journal
-
- Toukeibu Gan
-
Toukeibu Gan 44 (3), 310-315, 2018
Japan Society for Head and Neck Cancer
- Tweet
Details 詳細情報について
-
- CRID
- 1390001288097750400
-
- NII Article ID
- 130007529243
-
- ISSN
- 18818382
- 13495747
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
- KAKEN
- OpenAIRE
-
- Abstract License Flag
- Disallowed